Claritev (CTEV) Stock Price, News & Analysis

Company Overview

Claritev, formerly known as MultiPlan, provides technology-enabled services intended to help manage healthcare costs and support payment accuracy. Its offerings include access to provider networks, claims and payment solutions, and data analytics for evaluating healthcare costs and utilization.

The company serves health plans, self-insured employers, third-party administrators and other participants in the U.S. healthcare system. Its services are designed to help customers identify cost-management opportunities and support more efficient healthcare transactions.

Claritev’s business builds on MultiPlan’s longstanding role in the healthcare cost-management sector. The company operates primarily in the United States.

Key Stats

• Today's Range: $26.83 to $30.20
• 50-Day Range: $20.04 to $39.98
• 52-Week Range: $11.50 to $61.22
• Volume: 208,375 shs
• Average Volume: 174,691 shs
• Market Capitalization: $489.35 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $44.83
• Consensus Rating: Moderate Buy

Claritev Stock Analysis - MarketRank™

Claritev scored higher than 87% of companies evaluated by MarketBeat, and ranked 46th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Claritev has received a consensus rating of Moderate Buy. The company's average rating score is 2.56, and is based on no strong buy ratings, 6 buy ratings, 2 hold ratings, and 1 sell rating.

Upside Potential

Claritev has a consensus price target of $44.83, representing about 62.7% upside from its current price of $27.55.

Amount of Analyst Coverage

Claritev has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Claritev are expected to grow in the coming year, from ($15.13) to ($13.81) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Claritev is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Claritev is -1.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

4.91% of the float of Claritev has been sold short.

Short Interest Ratio / Days to Cover

Claritev has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Claritev has recently decreased by 16.06%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Claritev does not currently pay a dividend.

Dividend Growth

Claritev does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.45

News Sentiment

Claritev has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.57 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 12 news articles for Claritev this week, compared to 3 articles on an average week.

Company Ownership

• Score: 4.6 / 5
• Insider Trading: Acquiring Shares

Cluster Insider Buying

2 insiders have purchased shares of Claritev in the last three months. Multiple insiders buying is a strong bullish signal.

Net Insider Buying

Over the last three months, insiders have purchased a net $1,158,577.00 in company stock, which represents 0.2481% of the company's market cap.

Insider Buying vs. Insider Selling

In the past three months, Claritev insiders have bought 150.64% more of their company's stock than they have sold. Specifically, they have bought $1,927,655.00 in company stock and sold $769,078.00 in company stock.

Percentage Held by Insiders

7.40% of the stock of Claritev is held by insiders.

Percentage Held by Institutions

87.15% of the stock of Claritev is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 11/09/2026
• Today: 11/11/2026
• Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum: 11/11/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Healthcare
• Industry: Healthcare Technology
• Sub-Industry: Healthcare Technology
• Current Symbol: NYSE:CTEV
• CIK: 1793229
• Web: multiplan.us
• Phone: 1-800-677-1098
• Fax: N/A
• Employees: 2,500
• Year Founded: 1980

Price Target and Rating

• Average Price Target for Claritev: $44.83
• High Price Target: $73.00
• Low Price Target: $30.00
• Potential Upside/Downside: +55.6%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.56
• Research Coverage: 9 Analysts

Profitability

• EPS (Trailing Twelve Months): ($17.01)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$284.28 million
• Net Margins: -27.05%
• Pretax Margin: -37.16%
• Return on Equity: N/A
• Return on Assets: -5.70%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.00
• Quick Ratio: 1.00

Sales & Book Value

• Annual Sales: $965.41 million
• Price / Sales: 0.51
• Cash Flow: $18.59 per share
• Price / Cash Flow: 1.55
• Book Value: ($10.10) per share
• Price / Book: -2.85

Miscellaneous

• Outstanding Shares: 16,950,000
• Free Float: 15,693,000
• Market Cap: $488.50 million
• Optionable: Optionable
• Beta: 1.05